J.P. Morgan Healthcare Conference
Looking Good: Fresh from IPO, Kythera Spins Twin Chin Win
By Randy Osborne
Monday, January 7, 2013
With positive Phase III data in hand from European trials and more due this year from U.S. pivotal studies, Kythera Biopharmaceuticals Inc. offered attendees of the J.P. Morgan Healthcare Conference the company's game plan for earnings as "a new entrant into the established market of facial injectables," said Keith Leonard, co-founder, president and CEO.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.